End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
13.53 CNY | -0.51% | +3.20% | +20.16% |
Feb. 29 | Bloomage Biotech Names CFO | MT |
Feb. 08 | Guoquan Food Names CFO | MT |
Strengths
- The group's activity appears highly profitable thanks to its outperforming net margins.
- The equity is one of the most attractive in the market with regard to earnings multiple-based valuation.
- The company appears to be poorly valued given its net asset value.
- This company will be of major interest to investors in search of a high dividend stock.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
Weaknesses
- Over the past twelve months, analysts' opinions have been revised negatively.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Banks
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+20.16% | 7.14B | C- | ||
+9.63% | 197B | C+ | ||
+7.18% | 78.28B | A- | ||
+13.43% | 57.61B | C+ | ||
+0.25% | 46.71B | B- | ||
+7.50% | 45.14B | B- | ||
+13.23% | 38.84B | B- | ||
+13.32% | 37.08B | B | ||
-14.10% | 36.03B | A- | ||
-96.60% | 32.25B | - | D |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock
- Equities
- Stock Bank of Chengdu Co., Ltd. - Shanghai S.E.
- Ratings Bank of Chengdu Co., Ltd.